Avid Bioservices (CDMO) Financials

$12.50 +0.02 (+0.12%)

Closing price 02/5/2025

Extended Trading

$12.50 0.00 (0.00%)

As of 02/5/2025 04:23 PM Eastern

Annual Income Statements for Avid Bioservices

This table shows Avid Bioservices' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	4/30/2024	4/30/2023	4/30/2022	4/30/2021	4/30/2020	4/30/2019	4/30/2018	4/30/2017	4/30/2016	4/30/2015	4/30/2014
Net Income / (Loss) Attributable to Common Shareholders	-141	0.26	128	3.32	-15	-8.90	-26	-33	-60	-54	-36
Consolidated Net Income / (Loss)	-141	0.26	128	11	-10	-4.22	-22	-28	-56	-50	-35
Net Income / (Loss) Continuing Operations	-141	0.26	128	11	-10	-5.06	-21	1.39	3.60	-50	-35
Total Pre-Tax Income	-27	1.59	13	11	-10	-5.34	-21	1.39	3.60	-50	-35
Total Operating Income	-19	3.60	15	12	-11	-5.62	-21	1.29	3.49	-50	-36
Total Gross Profit	7.32	31	37	29	3.93	7.22	-2.92	19	21	11	22
Total Revenue	140	149	120	96	60	54	54	58	44	27	22
Operating Revenue	140	149	120	96	60	54	54	58	44	27	22
Total Cost of Revenue	133	118	83	67	56	46	57	38	23	16	0.00
Operating Cost of Revenue	133	118	83	67	56	46	57	38	23	16	-
Total Operating Expenses	26	28	21	17	15	13	18	18	18	62	58
Selling, General & Admin Expense	26	28	21	17	15	13	16	18	18	19	17
Total Other Income / (Expense), net	-8.25	-2.01	-2.76	-1.03	0.47	0.28	0.08	0.10	0.12	0.14	0.35
Interest Expense	4.34	3.01	2.68	1.16	0.01	0.01	-	-	-	-	-
Other Income / (Expense), net	-3.91	1.00	-0.08	0.13	0.48	-	-	-	-	-	-
Income Tax Expense	114	1.33	-115	0.00	0.00	-0.28	0.00	0.00	-	-	-
Basic Earnings per Share	($2.23)	$0.00	$2.08	$0.06	($0.27)	($0.16)	($0.56)	($0.88)	($1.95)	($2.07)	($0.22)
Weighted Average Basic Shares Outstanding	63.20M	62.27M	61.48M	58.22M	56.33M	55.98M	47.06M	37.11M	30.90M	26.08M	161.58M
Diluted Earnings per Share	($2.23)	$0.00	$1.84	$0.06	($0.27)	($0.16)	($0.56)	($0.88)	($1.95)	($2.07)	($0.22)
Weighted Average Diluted Shares Outstanding	63.20M	63.78M	70.47M	59.43M	56.33M	55.98M	47.06M	37.11M	30.90M	26.08M	161.58M
Weighted Average Basic & Diluted Shares Outstanding	63.58M	62.73M	61.83M	61.10M	56.33M	55.98M	47.06M	37.11M	30.90M	26.08M	161.58M

This table shows Avid Bioservices' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period end date	10/31/2024	7/31/2024	4/30/2024	1/31/2024	10/31/2023	7/31/2023	4/30/2023	1/31/2023	10/31/2022	7/31/2022	4/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-17	-5.53	-123	-6.01	-9.52	-2.12	-0.34	-0.25	-0.52	1.36	120
Consolidated Net Income / (Loss)	-17	-5.53	-123	-6.01	-9.52	-2.12	-0.34	-0.25	-0.52	1.36	120
Net Income / (Loss) Continuing Operations	-17	-5.53	-123	-6.01	-9.52	-2.12	-0.34	-0.25	-0.52	1.36	120
Total Pre-Tax Income	-17	-5.53	-5.23	-7.06	-12	-2.73	0.55	2.51	-3.42	1.94	7.35
Total Operating Income	-13	-2.46	-1.29	-4.00	-11	-2.16	0.83	2.72	-2.68	2.74	7.91
Total Gross Profit	-2.05	5.71	5.50	2.38	-4.67	4.10	8.39	9.83	4.15	9.12	12
Total Revenue	33	40	43	34	25	38	40	38	35	37	23
Operating Revenue	33	40	43	34	25	38	40	38	35	37	23
Total Cost of Revenue	36	34	37	31	30	34	31	28	31	28	11
Operating Cost of Revenue	36	34	37	31	30	34	31	28	31	28	11
Total Operating Expenses	11	8.17	6.79	6.38	6.56	6.26	7.56	7.11	6.83	6.38	4.12
Selling, General & Admin Expense	11	8.17	6.79	6.38	6.56	6.26	7.56	7.11	6.83	6.38	4.12
Total Other Income / (Expense), net	-4.78	-3.08	-3.94	-3.06	-0.69	-0.57	-0.28	-0.20	-0.73	-0.79	-0.56
Interest Expense	3.28	2.45	1.81	0.88	0.83	0.83	0.66	0.64	0.88	0.84	0.56
Other Income / (Expense), net	-1.50	-0.62	-2.13	-2.18	0.14	0.26	0.38	0.43	0.15	0.05	0.00
Income Tax Expense	0.00	0.00	118	-1.05	-2.39	-0.61	0.88	2.76	-2.90	0.58	-113
Basic Earnings per Share	($0.27)	($0.09)	($1.96)	($0.09)	($0.15)	($0.03)	($0.01)	$0.00	($0.01)	$0.02	$1.96
Weighted Average Basic Shares Outstanding	63.84M	63.64M	63.20M	63.32M	63.15M	62.84M	62.27M	62.39M	62.20M	61.91M	61.48M
Diluted Earnings per Share	($0.27)	($0.09)	($1.96)	($0.09)	($0.15)	($0.03)	($0.01)	$0.00	($0.01)	$0.02	$1.72
Weighted Average Diluted Shares Outstanding	63.84M	63.64M	63.20M	63.32M	63.15M	62.84M	63.78M	69.16M	62.20M	63.33M	70.47M
Weighted Average Basic & Diluted Shares Outstanding	63.96M	63.80M	63.58M	63.48M	63.24M	63.11M	62.73M	62.55M	-	62.17M	61.83M

This table details how cash moves in and out of Avid Bioservices' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	4/30/2024	4/30/2023	4/30/2022	4/30/2021	4/30/2020	4/30/2019	4/30/2018	4/30/2017	4/30/2016	4/30/2015	4/30/2014
Net Change in Cash & Equivalents	-0.79	-88	-44	134	3.11	-9.91	-4.53	-14	-6.59	-9.49	42
Net Cash From Operating Activities	11	-13	9.47	31	5.83	-12	-26	-39	-40	-36	-28
Net Cash From Continuing Operating Activities	11	-13	9.47	31	5.83	-7.05	-23	-36	-40	-36	-28
Net Income / (Loss) Continuing Operations	-141	0.26	128	11	-10	-4.22	-22	-28	-56	-50	-35
Consolidated Net Income / (Loss)	-141	0.26	128	11	-10	-4.22	-22	-28	-56	-50	-35
Depreciation Expense	11	7.21	4.48	3.45	3.09	2.75	2.56	2.46	1.54	1.04	0.99
Amortization Expense	1.50	1.05	1.03	0.92	0.00	0.00	-	-	-	-	-
Non-Cash Adjustments To Reconcile Net Income	12	-9.57	12	23	18	-6.09	-22	15	4.91	6.70	6.21
Changes in Operating Assets and Liabilities, net	127	-12	-135	-7.09	-4.81	0.51	18	-25	9.61	6.59	-0.09
Net Cash From Investing Activities	-32	-78	-56	-9.86	-3.81	4.54	-0.79	-3.06	-8.79	-8.45	-2.52
Net Cash From Continuing Investing Activities	-32	-78	-56	-9.86	-3.81	4.54	-0.79	-3.06	-8.79	-8.45	-2.52
Purchase of Property, Plant & Equipment	-32	-78	-56	-9.86	-3.81	-1.50	-3.79	-3.63	-8.88	-9.05	-0.76
Net Cash From Financing Activities	20	2.90	3.20	112	1.10	-2.86	22	28	42	35	73
Net Cash From Continuing Financing Activities	20	2.90	3.20	112	1.10	-2.86	22	28	42	35	73
Repayment of Debt	-143	-0.51	-0.16	-4.47	4.38	-0.07	-0.18	-0.14	0.00	-0.01	-0.03
Issuance of Debt	154	0.00	0.00	138	0.00	0.00	0.00	-	-	-	-
Issuance of Common Equity	1.40	3.41	3.36	36	1.12	1.54	26	31	46	20	54
Other Financing Activities, net	7.41	0.00	0.00	-13	-0.08	0.00	0.75	0.03	0.14	0.30	0.94
Cash Interest Paid	2.56	1.12	1.67	0.01	0.01	0.01	0.00	0.01	0.00	0.00	0.00
Cash Income Taxes Paid	0.02	0.26	0.06	0.00	0.00	-	-	-	-	-	-

This table details how cash moves in and out of Avid Bioservices' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period end date	10/31/2024	7/31/2024	4/30/2024	1/31/2024	10/31/2023	7/31/2023	4/30/2023	1/31/2023	10/31/2022	7/31/2022	4/30/2022
Net Change in Cash & Equivalents	0.03	-4.73	7.40	-0.72	6.18	-14	-21	-17	-38	-11	-24
Net Cash From Operating Activities	3.99	-3.68	1.26	3.69	6.24	-0.24	3.15	-6.94	-3.84	-5.09	0.61
Net Cash From Continuing Operating Activities	3.99	-3.68	1.26	3.69	6.24	-0.24	3.15	-6.94	-3.84	-5.09	0.61
Net Income / (Loss) Continuing Operations	-17	-5.53	-123	-6.01	-9.52	-2.12	-0.34	-0.25	-0.52	1.36	116
Consolidated Net Income / (Loss)	-17	-5.53	-123	-6.01	-9.52	-2.12	-0.34	-0.25	-0.52	1.36	116
Depreciation Expense	3.97	2.82	2.86	2.82	2.78	2.65	1.88	1.92	1.82	1.59	1.42
Amortization Expense	0.28	0.31	0.59	0.28	0.30	0.34	0.26	0.26	0.26	0.26	0.26
Non-Cash Adjustments To Reconcile Net Income	20	-1.41	-8.72	7.89	19	-6.79	3.99	-12	-0.96	-0.80	-5.19
Changes in Operating Assets and Liabilities, net	-2.74	0.13	130	-1.29	-6.53	5.69	-2.66	2.93	-4.44	-7.50	-111
Net Cash From Investing Activities	-3.45	-1.31	-5.69	-4.49	-7.47	-14	-25	-11	-34	-6.87	-25
Net Cash From Continuing Investing Activities	-3.45	-1.31	-5.69	-4.49	-7.47	-14	-25	-11	-34	-6.87	-25
Purchase of Property, Plant & Equipment	-3.45	-1.31	-5.69	-4.49	-7.47	-14	-25	-11	-34	-6.87	-25
Net Cash From Financing Activities	-0.51	0.27	12	0.09	7.40	0.75	0.70	0.87	0.40	0.93	0.16
Net Cash From Continuing Financing Activities	-0.51	0.27	12	0.09	7.40	0.75	0.70	0.87	0.40	0.93	0.16
Repayment of Debt	-0.62	-0.35	-142	-0.30	-0.13	-0.13	-0.13	-0.13	-0.17	-0.08	-0.16
Issuance of Common Equity	0.11	0.62	0.01	0.38	0.12	0.88	0.83	1.00	0.57	1.01	0.33
Cash Interest Paid	4.28	0.17	1.96	0.01	0.57	0.03	0.63	-0.26	0.73	0.02	0.76
Cash Income Taxes Paid	0.00	0.03	0.00	-	0.00	0.01	0.04	-	0.18	0.04	0.06

This table presents Avid Bioservices' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	4/30/2024	4/30/2023	4/30/2022	4/30/2021	4/30/2020	4/30/2019	4/30/2018	4/30/2017	4/30/2016	4/30/2015	4/30/2014
Total Assets	337	452	430	266	108	78	96	118	109	97	91
Total Current Assets	104	112	180	208	60	51	68	90	82	81	86
Cash & Equivalents	38	39	126	170	36	32	42	47	61	68	77
Accounts Receivable	17	18	21	19	8.61	7.37	3.75	7.74	2.86	3.81	1.33
Inventories, net	30	44	26	12	11	6.56	16	33	16	7.35	5.53
Prepaid Expenses	6.51	2.09	1.88	1.06	0.71	0.71	0.68	0.81	1.35	1.36	1.42
Other Current Assets	12	9.61	5.37	6.11	3.30	4.33	0.00	-	-	-	-
Plant, Property, & Equipment, net	187	178	93	37	27	26	26	26	24	15	2.45
Total Noncurrent Assets	46	161	157	20	21	1.45	1.45	2.19	2.93	1.82	2.33
Other Noncurrent Operating Assets	46	47	41	20	21	1.45	1.45	1.04	2.33	1.82	2.33
Total Liabilities & Shareholders' Equity	337	452	430	266	108	78	96	118	109	97	91
Total Liabilities	276	262	255	188	66	25	40	65	59	38	23
Total Current Liabilities	71	215	76	71	44	23	38	63	58	37	22
Accounts Payable	21	25	9.50	9.26	5.93	4.35	1.91	3.00	8.43	10	2.43
Current Deferred Revenue	40	37	54	-	-	-	-	46	34	18	11
Current Employee Benefit Liabilities	5.44	8.78	8.42	8.79	3.02	3.54	2.56	5.06	5.82	4.61	3.84
Other Current Liabilities	4.58	3.80	4.04	53	31	15	29	0.64	1.49	0.44	0.50
Total Noncurrent Liabilities	205	47	180	117	21	2.17	2.16	1.60	1.40	1.10	0.64
Long-Term Debt	154	0.00	140	97	0.00	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	52	47	40	20	21	0.09	-	-	-	-	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	61	189	175	78	42	53	56	54	50	59	68
Total Preferred & Common Equity	61	189	175	78	42	53	56	54	50	59	68
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	61	189	175	78	42	53	56	54	50	59	68
Common Stock	633	620	606	638	613	614	615	591	559	513	471
Retained Earnings	-572	-431	-431	-560	-571	-561	-559	-537	-509	-454	-403

This table presents Avid Bioservices' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q1 2023	Q3 2022
Period end date	10/31/2024	7/31/2024	1/31/2024	10/31/2023	7/31/2023	1/31/2023	7/31/2022	1/31/2022
Total Assets	323	335	455	455	443	450	451	314
Total Current Assets	97	104	104	104	98	132	181	203
Cash & Equivalents	33	33	31	31	25	60	115	150
Accounts Receivable	18	21	19	13	16	15	26	28
Inventories, net	28	29	35	39	41	45	30	21
Prepaid Expenses	4.80	5.87	7.58	9.97	1.89	2.11	2.12	1.13
Other Current Assets	12	14	12	11	14	10	7.08	3.34
Plant, Property, & Equipment, net	182	186	188	188	183	164	115	69
Total Noncurrent Assets	45	45	164	163	162	154	156	41
Other Noncurrent Operating Assets	45	45	46	47	47	39	41	41
Total Liabilities & Shareholders' Equity	323	335	455	455	443	450	451	314
Total Liabilities	279	276	275	272	253	265	272	258
Total Current Liabilities	74	71	223	219	206	87	93	77
Accounts Payable	9.25	20	20	23	23	36	30	6.46
Current Deferred Revenue	52	38	53	46	33	-	-	-
Current Employee Benefit Liabilities	8.22	5.61	4.11	4.24	4.67	8.40	5.30	7.74
Other Current Liabilities	5.01	7.82	4.90	4.66	4.56	43	58	63
Total Noncurrent Liabilities	205	205	52	53	47	178	179	180
Long-Term Debt	154	154	-	-	-	140	140	139
Other Noncurrent Operating Liabilities	50	51	52	53	45	37	39	41
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	45	59	180	183	190	185	179	57
Total Preferred & Common Equity	45	59	180	183	190	185	179	57
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	45	59	180	183	190	185	179	57
Common Stock	640	636	629	626	624	616	609	604
Retained Earnings	-595	-577	-449	-443	-433	-431	-430	-547

This table displays calculated financial ratios and metrics derived from Avid Bioservices' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	4/30/2024	4/30/2023	4/30/2022	4/30/2021	4/30/2020	4/30/2019	4/30/2018	4/30/2017	4/30/2016	4/30/2015	4/30/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-6.27%	24.81%	24.75%	60.58%	11.38%	-0.03%	-6.96%	29.92%	65.63%	19.55%	3.31%
EBITDA Growth	-177.60%	-38.33%	24.52%	327.30%	-156.15%	84.09%	-581.38%	-25.23%	110.15%	-42.45%	-27.34%
EBIT Growth	-590.77%	-70.00%	23.96%	218.34%	-86.02%	72.76%	-1,697.37%	-62.95%	106.91%	-41.43%	-25.94%
NOPAT Growth	-2,328.96%	-99.62%	1,170.22%	259.87%	-94.59%	72.76%	-1,218.16%	-62.95%	109.86%	-41.43%	-25.94%
Net Income Growth	-54,444.79%	-99.80%	1,038.71%	207.13%	-148.30%	80.68%	22.54%	49.40%	-10.51%	-42.41%	-18.74%
EPS Growth	0.00%	-100.00%	2,966.67%	122.22%	-68.75%	71.43%	36.36%	54.87%	5.80%	-840.91%	12.00%
Operating Cash Flow Growth	186.09%	-234.41%	-69.65%	435.13%	150.25%	55.39%	33.64%	1.07%	-9.92%	-27.48%	-35.02%
Free Cash Flow Firm Growth	198.69%	-276.24%	-256.14%	474.06%	126.19%	20.02%	38.33%	-465.01%	117.86%	-35.75%	-57.19%
Invested Capital Growth	-39.34%	55.07%	3,832.64%	-52.36%	-51.67%	59.08%	0.72%	208.31%	-33.15%	8.43%	14.44%
Revenue Q/Q Growth	2.32%	13.04%	-4.03%	18.63%	-7.02%	23.25%	-16.97%	-0.95%	25.97%	11.83%	11.00%
EBITDA Q/Q Growth	-50.05%	-32.66%	28.24%	117.95%	-143.78%	68.80%	-395.99%	-88.84%	109.06%	-3.45%	-6.43%
EBIT Q/Q Growth	-25.76%	-59.28%	44.67%	185.95%	-73.20%	52.52%	-681.52%	-95.86%	106.16%	-3.36%	-6.14%
NOPAT Q/Q Growth	-12.84%	-99.62%	1,366.56%	182.88%	-81.19%	52.52%	-507.06%	-95.86%	108.80%	-3.36%	-6.14%
Net Income Q/Q Growth	-682.66%	-99.79%	1,260.09%	151.79%	-95.19%	-175.31%	27.54%	19.02%	0.45%	-3.89%	-5.36%
EPS Q/Q Growth	-696.43%	-100.00%	1,740.00%	0.00%	0.00%	0.00%	0.00%	64.66%	5.80%	-613.79%	0.00%
Operating Cash Flow Q/Q Growth	-14.70%	16.60%	-64.57%	90.49%	-30.86%	23.38%	34.45%	-17.86%	-8.82%	10.22%	-6.78%
Free Cash Flow Firm Q/Q Growth	376.75%	-55.24%	-30.95%	180.09%	-18.91%	42.52%	-32.23%	-191.53%	117.21%	1.87%	-9.67%
Invested Capital Q/Q Growth	-39.34%	9.43%	308.41%	-67.05%	-38.91%	-15.00%	4.76%	711.64%	-58.39%	-64.70%	-20.79%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	5.23%	21.09%	30.64%	30.57%	6.59%	13.48%	-5.45%	33.61%	48.22%	41.78%	100.00%
EBITDA Margin	-7.13%	8.61%	17.43%	17.47%	-12.34%	-5.37%	-33.71%	6.52%	11.32%	-184.68%	-154.99%
Operating Margin	-13.35%	2.41%	12.90%	12.77%	-18.32%	-10.49%	-38.49%	2.24%	7.86%	-188.56%	-159.39%
EBIT Margin	-16.15%	3.08%	12.83%	12.91%	-17.52%	-10.49%	-38.49%	2.24%	7.86%	-188.56%	-159.39%
Profit (Net Income) Margin	-100.60%	0.17%	106.75%	11.70%	-17.53%	-7.86%	-40.68%	-48.86%	-125.46%	-188.04%	-157.86%
Tax Burden Percent	522.72%	16.29%	1,008.39%	100.00%	100.00%	78.93%	106.08%	-2,021.46%	-1,547.18%	100.00%	100.01%
Interest Burden Percent	119.20%	34.54%	82.53%	90.59%	100.08%	94.98%	99.64%	107.82%	103.15%	99.72%	99.02%
Effective Tax Rate	0.00%	83.71%	-908.39%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-5.60%	0.25%	161.69%	165.64%	-49.84%	-23.33%	-111.33%	260.48%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-123.11%	-0.33%	254.65%	167.60%	-41.10%	-22.58%	-93.66%	317.86%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-106.98%	-0.10%	-60.47%	-146.89%	27.80%	15.58%	71.42%	-314.82%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-112.58%	0.14%	101.22%	18.74%	-22.04%	-7.75%	-39.91%	-54.33%	-102.01%	-79.47%	-77.33%
Cash Return on Invested Capital (CROIC)	43.38%	-42.94%	-28.39%	236.57%	19.82%	-68.94%	-112.05%	-182.34%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-5.73%	1.04%	4.41%	6.63%	-11.24%	-6.46%	-19.30%	1.14%	3.38%	-53.72%	-52.66%
Return on Assets (ROA)	-35.72%	0.06%	36.72%	6.01%	-11.25%	-4.84%	-20.40%	-24.79%	-53.90%	-53.57%	-52.16%
Return on Common Equity (ROCE)	-112.58%	0.14%	101.22%	18.74%	-22.04%	-7.75%	-39.91%	-54.33%	-102.01%	-79.47%	-77.33%
Return on Equity Simple (ROE_SIMPLE)	-231.16%	0.14%	73.15%	14.42%	-24.98%	-7.94%	-39.13%	-52.55%	-111.14%	-85.30%	-52.23%
Net Operating Profit after Tax (NOPAT)	-13	0.59	156	12	-7.66	-3.94	-14	1.29	3.49	-35	-25
NOPAT Margin	-9.34%	0.39%	130.03%	12.77%	-12.83%	-7.34%	-26.94%	2.24%	7.86%	-131.99%	-111.58%
Net Nonoperating Expense Percent (NNEP)	117.52%	0.57%	-92.95%	-1.97%	-8.74%	-0.74%	-17.67%	-57.37%	-90.97%	-20.63%	-18.40%
Cost of Revenue to Revenue	94.77%	78.91%	69.36%	69.43%	93.41%	86.52%	105.45%	66.39%	51.78%	58.22%	0.00%
SG&A Expenses to Revenue	18.58%	18.68%	17.75%	17.80%	24.32%	23.97%	30.69%	31.37%	40.40%	69.80%	77.13%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	160.55%	123.76%
Operating Expenses to Revenue	18.58%	18.68%	17.75%	17.80%	24.91%	23.97%	33.04%	31.37%	40.40%	230.34%	259.42%
Earnings before Interest and Taxes (EBIT)	-23	4.60	15	12	-10	-5.62	-21	1.29	3.49	-50	-36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-9.98	13	21	17	-7.37	-2.88	-18	3.76	5.02	-49	-35
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.95	5.97	4.76	16.75	8.22	5.06	3.66	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	7.95	5.97	4.76	16.75	8.22	5.06	3.66	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.46	7.56	6.95	13.58	5.77	5.01	3.80	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	4,358.97	6.51	392.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.02%	15.36%	0.25%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.40	4.23	4.50	257.67	31.23	11.40	12.41	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	4.29	8.25	7.06	12.82	5.24	4.41	3.01	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	95.71	40.48	73.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	267.37	55.03	99.31	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	2,098.11	5.43	100.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	54.77	0.00	89.19	39.42	53.66	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	5.92	0.00	0.00	70.29	102.65	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.52	0.74	0.80	1.25	0.10	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	2.52	0.00	0.80	1.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.87	0.32	-0.24	-0.88	-0.68	-0.69	-0.76	-0.99	-1.19	-1.15	-1.23
Leverage Ratio	3.15	2.42	2.76	3.12	1.96	1.60	1.96	2.19	1.89	1.48	1.48
Compound Leverage Factor	3.76	0.84	2.27	2.83	1.96	1.52	1.95	2.36	1.95	1.48	1.47
Debt to Total Capital	71.61%	42.64%	44.44%	55.50%	9.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	42.64%	0.00%	0.00%	9.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	71.61%	0.00%	44.44%	55.50%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	28.39%	57.36%	55.56%	44.50%	90.53%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-15.39	10.94	6.69	5.79	-0.59	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-11.57	7.91	0.63	-4.36	4.33	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-15.39	0.00	6.69	5.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-11.75	239.73	0.90	7.92	-0.57	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-8.83	173.43	0.08	-5.96	4.16	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-11.75	0.00	0.90	7.92	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.01	1.34	1.24	2.34	-3.88	-2.77	-4.89	0.00	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.47	0.52	2.38	2.93	1.34	2.22	1.79	1.43	1.42	2.16	3.86
Quick Ratio	0.78	0.26	1.94	2.66	1.01	1.72	1.22	0.87	1.12	1.92	3.55
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	101	-103	-27	17	3.05	-12	-15	-24	6.46	-36	-27
Operating Cash Flow to CapEx	34.43%	-16.35%	16.78%	316.12%	152.86%	0.00%	-685.26%	-1,079.93%	-445.95%	-398.13%	-3,742.25%
Free Cash Flow to Firm to Interest Expense	23.38	-34.09	-10.19	15.02	380.75	-1,057.22	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	2.53	-4.22	3.53	26.79	728.38	-1,054.09	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-4.81	-30.04	-17.52	18.31	251.88	-641.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.36	0.34	0.34	0.51	0.64	0.62	0.50	0.51	0.43	0.28	0.33
Accounts Receivable Turnover	8.01	7.69	6.07	6.99	7.47	9.63	9.33	10.87	13.30	10.41	14.96
Inventory Turnover	3.57	3.37	4.37	5.85	6.40	4.09	2.30	1.55	1.95	2.42	0.00
Fixed Asset Turnover	0.77	1.10	1.83	2.97	2.26	2.06	2.04	2.29	2.25	3.05	8.74
Accounts Payable Turnover	5.86	6.91	8.84	8.77	10.85	14.82	23.04	6.70	2.44	2.43	0.00
Days Sales Outstanding (DSO)	45.58	47.49	60.11	52.25	48.85	37.89	39.13	33.57	27.45	35.06	24.39
Days Inventory Outstanding (DIO)	102.24	108.41	83.46	62.39	57.07	89.27	158.88	235.10	187.06	150.79	0.00
Days Payable Outstanding (DPO)	62.30	52.83	41.28	41.63	33.63	24.64	15.84	54.52	149.51	150.03	0.00
Cash Conversion Cycle (CCC)	85.53	103.08	102.29	73.01	72.29	102.52	182.17	214.15	65.01	35.82	24.39
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	176	291	188	4.77	10	21	13	13	-12	-8.97	-9.79
Invested Capital Turnover	0.60	0.62	1.24	12.97	3.89	3.18	4.13	116.19	-4.24	-2.86	-2.11
Increase / (Decrease) in Invested Capital	-114	103	183	-5.24	-11	7.69	0.09	25	-2.97	0.83	1.65
Enterprise Value (EV)	600	1,231	844	1,229	313	236	162	0.00	0.00	0.00	0.00
Market Capitalization	484	1,129	831	1,302	345	269	204	0.00	0.00	0.00	0.00
Book Value per Share	$0.96	$3.02	$2.83	$1.28	$0.74	$0.95	$1.00	$0.18	$0.21	$0.31	$0.38
Tangible Book Value per Share	$0.96	$3.02	$2.83	$1.28	$0.74	$0.95	$1.00	$0.18	$0.21	$0.31	$0.38
Total Capital	214	330	314	175	46	53	56	54	50	59	68
Total Debt	154	141	140	97	4.38	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	154	0.00	140	97	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	115	102	13	-73	-32	-32	-42	-47	-61	-68	-77
Capital Expenditures (CapEx)	32	78	56	9.86	3.81	-4.54	3.79	3.63	8.88	9.05	0.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-4.67	-0.96	-22	-33	-17	-4.20	-12	-20	-37	-25	-14
Debt-free Net Working Capital (DFNWC)	33	38	104	137	20	28	30	27	24	43	64
Net Working Capital (NWC)	33	-103	104	137	15	28	30	27	24	43	64
Net Nonoperating Expense (NNE)	128	0.33	28	1.03	2.81	0.28	7.37	29	59	15	10
Net Nonoperating Obligations (NNO)	116	102	13	-73	-32	-32	-43	-41	-62	-68	-77
Total Depreciation and Amortization (D&A)	13	8.26	5.51	4.37	3.09	2.75	2.56	2.46	1.54	1.04	0.99
Debt-free, Cash-free Net Working Capital to Revenue	-3.34%	-0.65%	-18.61%	-34.47%	-27.80%	-7.83%	-22.94%	-34.45%	-83.82%	-92.64%	-62.17%
Debt-free Net Working Capital to Revenue	23.90%	25.41%	87.18%	142.77%	32.93%	52.53%	55.88%	46.75%	54.63%	161.28%	283.76%
Net Working Capital to Revenue	23.90%	-68.80%	87.18%	142.77%	25.60%	52.53%	55.88%	46.75%	54.63%	161.28%	283.76%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.23)	$0.00	$2.08	$0.06	($0.27)	($0.16)	($0.56)	($0.88)	($0.28)	($0.30)	($0.22)
Adjusted Weighted Average Basic Shares Outstanding	63.20M	0.00	61.48M	58.22M	56.51M	56.14M	55.79M	45.07M	241.46M	199.93M	179.21M
Adjusted Diluted Earnings per Share	($2.23)	$0.00	$1.84	$0.06	($0.27)	($0.16)	($0.56)	($0.88)	($0.28)	($0.30)	($0.22)
Adjusted Weighted Average Diluted Shares Outstanding	63.20M	0.00	70.47M	59.43M	56.51M	56.14M	55.79M	45.07M	241.46M	199.93M	179.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.06	($0.27)	($0.16)	($0.56)	($0.88)	($0.28)	($0.30)	($0.22)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	63.58M	0.00	61.83M	61.10M	56.33M	55.98M	47.06M	37.11M	216.27M	182.56M	161.58M
Normalized Net Operating Profit after Tax (NOPAT)	-13	2.52	11	8.57	-7.66	-3.94	-14	0.90	2.44	-35	-25
Normalized NOPAT Margin	-9.34%	1.69%	9.03%	8.94%	-12.83%	-7.34%	-25.30%	1.57%	5.50%	-131.99%	-111.58%
Pre Tax Income Margin	-19.25%	1.07%	10.59%	11.70%	-17.53%	-9.96%	-38.35%	2.42%	8.11%	-188.03%	-157.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.21	1.53	5.72	10.63	-1,307.25	-511.09	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-3.01	0.19	58.03	10.52	-957.25	-357.76	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-12.54	-24.29	-15.32	2.16	-1,783.75	-98.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-10.35	-25.63	36.98	2.04	-1,433.75	55.33	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	39.73%	-41.32%	-102.61%	-19.83%	-15.20%	-7.44%	-6.66%	-0.66%
Augmented Payout Ratio	0.00%	0.00%	0.00%	39.73%	-41.32%	-102.61%	-19.83%	-15.20%	-7.44%	-6.66%	-0.66%

This table displays calculated financial ratios and metrics derived from Avid Bioservices' official financial filings.

Metric	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period end date	10/31/2024	7/31/2024	4/30/2024	1/31/2024	10/31/2023	7/31/2023	4/30/2023	1/31/2023	10/31/2022	7/31/2022	4/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	31.84%	6.49%	7.98%	-11.06%	-26.94%	2.82%	76.27%	20.66%	0.00%	19.31%	-18.21%
EBITDA Growth	-23.51%	-95.48%	-99.20%	-157.98%	-1,638.70%	-76.63%	-65.02%	25.48%	-462.20%	-43.95%	95.06%
EBIT Growth	-27.50%	-61.68%	-383.35%	-296.29%	-336.47%	-168.40%	-84.74%	6.20%	0.00%	-60.25%	156.06%
NOPAT Growth	-12.56%	-13.55%	-78.09%	-948.26%	-318.11%	-179.07%	-100.39%	-108.17%	0.00%	-72.37%	4,089.02%
Net Income Growth	-82.82%	-160.79%	-36,647.46%	-2,331.58%	-1,730.96%	-255.91%	-100.28%	-110.99%	55.02%	-78.41%	5,940.98%
EPS Growth	-80.00%	-200.00%	-19,500.00%	0.00%	-1,400.00%	-250.00%	-100.58%	-100.00%	50.00%	-80.00%	8,700.00%
Operating Cash Flow Growth	-36.03%	-1,459.32%	-60.03%	153.12%	262.73%	95.36%	413.89%	-233.69%	-109.79%	26.69%	-96.57%
Free Cash Flow Firm Growth	139.44%	220.30%	209.37%	87.35%	-224.28%	47.89%	-94.20%	-681.15%	204.29%	-757.56%	-741.70%
Invested Capital Growth	-43.51%	-41.72%	-39.34%	9.42%	0.00%	50.88%	55.07%	478.78%	0.00%	0.00%	3,832.64%
Revenue Q/Q Growth	-16.66%	-6.52%	27.09%	33.16%	-32.69%	-5.21%	4.68%	9.38%	-5.27%	62.51%	-28.34%
EBITDA Q/Q Growth	-20,259.18%	81.48%	100.87%	61.37%	-838.50%	-67.72%	-37.04%	1,258.48%	-109.92%	-51.67%	125.83%
EBIT Q/Q Growth	-358.77%	9.94%	44.69%	44.21%	-481.73%	-257.83%	-61.68%	224.06%	-191.17%	-64.78%	166.59%
NOPAT Q/Q Growth	-414.29%	-89.80%	67.64%	64.36%	-418.82%	-197.69%	-90.46%	85.79%	-198.12%	-98.52%	3,857.08%
Net Income Q/Q Growth	-214.53%	95.50%	-1,949.68%	36.92%	-348.68%	-533.43%	-35.63%	52.50%	-138.21%	-98.87%	5,250.36%
EPS Q/Q Growth	-200.00%	95.41%	-2,077.78%	40.00%	-400.00%	-200.00%	0.00%	100.00%	-150.00%	-98.84%	4,200.00%
Operating Cash Flow Q/Q Growth	208.53%	-392.76%	-65.91%	-40.95%	2,745.76%	-107.50%	145.31%	-80.90%	24.60%	-931.54%	-88.21%
Free Cash Flow Firm Q/Q Growth	-6.17%	11.40%	507.79%	90.75%	-186.19%	-1.28%	52.85%	-190.94%	219.99%	-277.45%	-89.67%
Invested Capital Q/Q Growth	-7.58%	1.52%	-39.34%	-0.74%	-4.64%	5.65%	9.43%	0.00%	-100.00%	8.59%	308.41%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	-6.11%	14.22%	12.80%	7.05%	-18.37%	10.87%	21.08%	25.84%	11.93%	24.85%	53.25%
EBITDA Margin	-29.50%	0.12%	0.06%	-9.14%	-31.49%	2.87%	8.43%	14.02%	-1.32%	12.63%	42.48%
Operating Margin	-37.72%	-6.11%	-3.01%	-11.83%	-44.19%	-5.73%	2.09%	7.15%	-7.72%	7.45%	35.02%
EBIT Margin	-42.20%	-7.67%	-7.96%	-18.28%	-43.64%	-5.05%	3.03%	8.29%	-7.31%	7.59%	35.02%
Profit (Net Income) Margin	-51.99%	-13.78%	-286.45%	-17.76%	-37.49%	-5.62%	-0.84%	-0.65%	-1.50%	3.71%	532.71%
Tax Burden Percent	100.00%	100.00%	2,353.81%	85.09%	79.95%	77.73%	-61.13%	-9.83%	15.22%	70.01%	1,636.19%
Interest Burden Percent	123.18%	179.68%	152.92%	114.15%	107.46%	143.31%	45.40%	79.81%	134.54%	69.80%	92.97%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	161.13%	109.83%	0.00%	29.99%	-1,536.19%
Return on Invested Capital (ROIC)	-17.33%	-2.50%	-1.26%	-4.07%	-29.75%	-2.36%	-0.80%	-0.60%	0.00%	6.43%	712.44%
ROIC Less NNEP Spread (ROIC-NNEP)	-24.76%	-5.72%	-113.74%	-7.42%	-32.79%	-3.22%	-0.49%	-0.54%	0.00%	1.95%	742.75%
Return on Net Nonoperating Assets (RNNOA)	-25.01%	-5.46%	-98.83%	-3.88%	-19.62%	-1.24%	-0.16%	-0.16%	0.00%	0.27%	-176.38%
Return on Equity (ROE)	-42.34%	-7.96%	-100.09%	-7.95%	-49.38%	-3.60%	-0.95%	-0.75%	0.00%	6.70%	536.05%
Cash Return on Invested Capital (CROIC)	49.39%	47.25%	43.38%	-13.16%	-204.70%	-40.91%	-42.94%	-42.45%	0.00%	-37.04%	-28.39%
Operating Return on Assets (OROA)	-16.30%	-2.81%	-2.83%	-5.52%	-13.50%	-1.70%	1.03%	2.86%	0.00%	2.11%	12.05%
Return on Assets (ROA)	-20.08%	-5.04%	-101.71%	-5.36%	-11.60%	-1.89%	-0.29%	-0.22%	0.00%	1.03%	183.25%
Return on Common Equity (ROCE)	-42.34%	-7.96%	-100.09%	-7.95%	-49.38%	-3.60%	-0.95%	-0.75%	0.00%	6.70%	536.05%
Return on Equity Simple (ROE_SIMPLE)	-339.34%	-245.86%	0.00%	-9.98%	-6.67%	-1.69%	0.00%	65.20%	0.00%	68.56%	0.00%
Net Operating Profit after Tax (NOPAT)	-8.84	-1.72	-0.91	-2.80	-7.86	-1.51	-0.51	-0.27	-1.88	1.91	129
NOPAT Margin	-26.41%	-4.28%	-2.11%	-8.28%	-30.93%	-4.01%	-1.28%	-0.70%	-5.41%	5.22%	572.93%
Net Nonoperating Expense Percent (NNEP)	7.43%	3.21%	112.47%	3.36%	3.04%	0.86%	-0.30%	-0.06%	0.00%	4.48%	-30.32%
Return On Investment Capital (ROIC_SIMPLE)	-4.44%	-	-	-	-2.42%	-	-	-	-	-	-
Cost of Revenue to Revenue	106.11%	85.78%	87.20%	92.95%	118.37%	89.13%	78.92%	74.16%	88.07%	75.15%	46.75%
SG&A Expenses to Revenue	31.62%	20.33%	15.81%	18.87%	25.82%	16.60%	18.99%	18.69%	19.65%	17.39%	18.23%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	31.62%	20.33%	15.81%	18.87%	25.82%	16.60%	18.99%	18.69%	19.65%	17.39%	18.23%
Earnings before Interest and Taxes (EBIT)	-14	-3.08	-3.42	-6.18	-11	-1.91	1.21	3.15	-2.54	2.79	7.91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-9.88	0.05	0.03	-3.09	-8.00	1.08	3.36	5.33	-0.46	4.64	9.59
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	14.18	11.32	7.95	2.38	2.12	4.17	5.97	5.32	0.00	6.79	4.76
Price to Tangible Book Value (P/TBV)	14.18	11.32	7.95	2.38	2.12	4.17	5.97	5.32	0.00	6.79	4.76
Price to Revenue (P/Rev)	4.22	4.66	3.46	3.13	2.75	5.28	7.56	7.47	8.39	9.68	6.95
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	4,358.97	8.16	8.54	9.90	6.51
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.02%	12.25%	11.71%	10.10%	15.36%
Enterprise Value to Invested Capital (EV/IC)	4.57	4.38	3.40	1.85	1.70	2.96	4.23	4.01	0.00	6.09	4.50
Enterprise Value to Revenue (EV/Rev)	5.03	5.51	4.29	3.94	3.53	6.06	8.25	8.08	0.00	9.88	7.06
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	281.44	97.91	95.71	55.87	0.00	72.01	40.48
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	267.37	94.38	0.00	111.50	55.03
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	2,098.11	6.94	0.00	7.47	5.43
Enterprise Value to Operating Cash Flow (EV/OCF)	143.81	104.46	54.77	41.97	225.08	0.00	0.00	0.00	0.00	109.54	89.19
Enterprise Value to Free Cash Flow (EV/FCFF)	6.68	6.82	5.92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.44	2.62	2.52	0.78	0.77	0.75	0.74	0.76	0.00	0.78	0.80
Long-Term Debt to Equity	3.44	2.62	2.52	0.00	0.00	0.01	0.00	0.76	0.00	0.78	0.80
Financial Leverage	1.01	0.95	0.87	0.52	0.60	0.38	0.32	0.29	0.00	0.14	-0.24
Leverage Ratio	3.41	3.12	3.15	2.48	2.48	2.42	2.42	3.16	0.00	2.52	2.76
Compound Leverage Factor	4.21	5.61	4.82	2.83	2.67	3.47	1.10	2.52	0.00	1.76	2.56
Debt to Total Capital	77.48%	72.41%	71.61%	43.98%	43.50%	42.79%	42.64%	43.09%	0.00%	43.86%	44.44%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	43.98%	43.50%	42.36%	42.64%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	77.48%	72.41%	71.61%	0.00%	0.00%	0.43%	0.00%	43.09%	0.00%	43.86%	44.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	22.52%	27.59%	28.39%	56.02%	56.50%	57.21%	57.36%	56.91%	0.00%	56.14%	55.56%
Debt to EBITDA	-11.96	-13.97	-15.39	-21.27	79.79	15.29	10.94	7.35	0.00	8.12	6.69
Net Debt to EBITDA	-9.36	-10.94	-11.57	-16.65	62.03	12.58	7.91	4.21	0.00	1.43	0.63
Long-Term Debt to EBITDA	-11.96	-13.97	-15.39	0.00	0.00	0.15	0.00	7.35	0.00	8.12	6.69
Debt to NOPAT	-10.81	-11.59	-11.75	-12.21	-20.50	-156.75	239.73	0.91	0.00	0.84	0.90
Net Debt to NOPAT	-8.46	-9.07	-8.83	-9.56	-15.94	-128.94	173.43	0.52	0.00	0.15	0.08
Long-Term Debt to NOPAT	-10.81	-11.59	-11.75	0.00	0.00	-1.57	0.00	0.91	0.00	0.84	0.90
Altman Z-Score	-0.80	-0.46	-0.82	-0.51	-0.58	0.55	1.31	1.33	0.00	1.88	1.18
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.30	1.46	1.47	0.46	0.48	0.48	0.52	1.52	0.00	1.94	2.38
Quick Ratio	0.70	0.76	0.78	0.22	0.20	0.20	0.26	0.86	0.00	1.51	1.94
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	119	126	114	-28	-301	-105	-104	-220	242	-202	-53
Operating Cash Flow to CapEx	115.87%	-280.70%	22.08%	82.15%	83.61%	-1.67%	12.47%	-61.41%	-11.15%	-74.09%	2.49%
Free Cash Flow to Firm to Interest Expense	36.23	51.54	62.73	-31.82	-363.87	-127.45	-157.54	-346.19	276.08	-239.93	-96.15
Operating Cash Flow to Interest Expense	1.22	-1.50	0.69	4.21	7.55	-0.29	4.77	-10.91	-4.38	-6.05	1.10
Operating Cash Flow Less CapEx to Interest Expense	0.17	-2.03	-2.45	-0.92	-1.48	-17.44	-33.50	-28.69	-43.61	-14.22	-43.08
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.39	0.37	0.36	0.30	0.31	0.34	0.34	0.35	0.00	0.28	0.34
Accounts Receivable Turnover	9.46	7.66	8.01	8.20	10.53	7.13	7.69	6.17	0.00	4.84	6.07
Inventory Turnover	4.17	3.81	3.57	3.18	3.20	3.48	3.37	2.93	0.00	3.00	4.37
Fixed Asset Turnover	0.81	0.77	0.77	0.78	0.75	1.01	1.10	1.13	0.00	1.09	1.83
Accounts Payable Turnover	8.67	6.23	5.86	4.53	5.41	4.65	6.91	4.52	0.00	2.99	8.84
Days Sales Outstanding (DSO)	38.56	47.65	45.58	44.53	34.65	51.19	47.49	59.20	0.00	75.44	60.11
Days Inventory Outstanding (DIO)	87.58	95.83	102.24	114.92	114.23	104.96	108.41	124.55	0.00	121.53	83.46
Days Payable Outstanding (DPO)	42.09	58.56	62.30	80.64	67.45	78.51	52.83	80.67	0.00	121.96	41.28
Cash Conversion Cycle (CCC)	84.05	84.92	85.53	78.81	81.42	77.63	103.08	103.09	0.00	75.01	102.29
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	166	179	176	291	293	307	291	266	0.00	204	188
Invested Capital Turnover	0.66	0.59	0.60	0.49	0.96	0.59	0.62	0.85	0.00	1.23	1.24
Increase / (Decrease) in Invested Capital	-128	-128	-114	25	293	104	103	220	-244	204	183
Enterprise Value (EV)	756	784	600	539	498	911	1,231	1,067	0.00	1,240	844
Market Capitalization	635	664	484	428	388	794	1,129	986	1,053	1,215	831
Book Value per Share	$0.70	$0.92	$0.96	$2.85	$2.90	$3.03	$3.02	$2.98	$0.00	$2.89	$2.83
Tangible Book Value per Share	$0.70	$0.92	$0.96	$2.85	$2.90	$3.03	$3.02	$2.98	$0.00	$2.89	$2.83
Total Capital	199	213	214	322	324	333	330	326	0.00	319	314
Total Debt	154	154	154	141	141	142	141	140	0.00	140	140
Total Long-Term Debt	154	154	154	0.00	0.00	1.42	0.00	140	0.00	140	140
Net Debt	121	120	115	111	110	117	102	80	0.00	25	13
Capital Expenditures (CapEx)	3.45	1.31	5.69	4.49	7.47	14	25	11	34	6.87	25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-11	-0.84	-4.67	-8.59	-5.34	8.02	-0.96	-15	0.00	-28	-22
Debt-free Net Working Capital (DFNWC)	22	33	33	22	26	33	38	45	0.00	87	104
Net Working Capital (NWC)	22	33	33	-119	-115	-108	-103	45	0.00	87	104
Net Nonoperating Expense (NNE)	8.56	3.81	122	3.21	1.67	0.61	-0.17	-0.02	-1.36	0.55	9.08
Net Nonoperating Obligations (NNO)	121	120	116	111	110	117	102	80	0.00	25	13
Total Depreciation and Amortization (D&A)	4.25	3.13	3.45	3.09	3.08	2.99	2.15	2.18	2.08	1.85	1.68
Debt-free, Cash-free Net Working Capital to Revenue	-7.36%	-0.59%	-3.34%	-6.28%	-3.79%	5.33%	-0.65%	-11.28%	0.00%	-22.18%	-18.61%
Debt-free Net Working Capital to Revenue	14.86%	22.86%	23.90%	16.18%	18.51%	22.13%	25.41%	34.10%	0.00%	69.54%	87.18%
Net Working Capital to Revenue	14.86%	22.86%	23.90%	-87.25%	-81.65%	-71.61%	-68.80%	34.10%	0.00%	69.54%	87.18%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.27)	($0.09)	($1.96)	($0.09)	$0.00	$0.00	($0.01)	$0.01	$0.00	$0.03	$1.96
Adjusted Weighted Average Basic Shares Outstanding	63.84M	63.64M	63.20M	63.32M	0.00	0.00	62.27M	62.39M	0.00	61.91M	61.48M
Adjusted Diluted Earnings per Share	($0.27)	($0.09)	($1.96)	($0.09)	$0.00	$0.00	($0.01)	$0.01	$0.00	$0.02	$1.72
Adjusted Weighted Average Diluted Shares Outstanding	63.84M	63.64M	63.20M	63.32M	0.00	0.00	63.78M	63.73M	0.00	63.33M	70.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	63.96M	63.80M	63.58M	63.48M	0.00	0.00	62.73M	62.55M	0.00	62.17M	61.83M
Normalized Net Operating Profit after Tax (NOPAT)	-8.84	-1.72	-0.91	-2.80	-7.86	-1.51	0.58	1.90	-1.88	1.91	5.53
Normalized NOPAT Margin	-26.41%	-4.28%	-2.11%	-8.28%	-30.93%	-4.01%	1.46%	5.00%	-5.41%	5.22%	24.51%
Pre Tax Income Margin	-51.99%	-13.78%	-12.17%	-20.87%	-46.90%	-7.24%	1.38%	6.61%	-9.83%	5.30%	32.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.31	-1.26	-1.89	-7.07	-13.40	-2.31	1.83	4.95	-2.90	3.31	14.22
NOPAT to Interest Expense	-2.70	-0.70	-0.50	-3.20	-9.50	-1.84	-0.77	-0.42	-2.14	2.28	232.66
EBIT Less CapEx to Interest Expense	-5.37	-1.79	-5.03	-12.20	-22.43	-19.47	-36.44	-12.82	-42.13	-4.86	-29.96
NOPAT Less CapEx to Interest Expense	-3.75	-1.23	-3.65	-8.33	-18.53	-18.99	-39.05	-18.19	-41.38	-5.89	188.47
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Avid Bioservices' Financials

When does Avid Bioservices's fiscal year end?

According to the most recent income statement we have on file, Avid Bioservices' financial year ends in April. Their financial year 2024 ended on April 30, 2024.

How has Avid Bioservices' net income changed over the last 10 years?

Avid Bioservices' net income appears to be on a downward trend, with a most recent value of -$140.75 million in 2024, rising from -$35.36 million in 2014. The previous period was $259 thousand in 2023. Find out what analysts predict for Avid Bioservices in the coming months.

What is Avid Bioservices's operating income?

Avid Bioservices's total operating income in 2024 was -$18.68 million, based on the following breakdown:

Total Gross Profit: $7.32 million
Total Operating Expenses: $26.00 million

How has Avid Bioservices revenue changed over the last 10 years?

Over the last 10 years, Avid Bioservices' total revenue changed from $22.40 million in 2014 to $139.91 million in 2024, a change of 524.6%.

How much debt does Avid Bioservices have?

Avid Bioservices' total liabilities were at $275.67 million at the end of 2024, a 5.1% increase from 2023, and a 1,106.6% increase since 2014.

How much cash does Avid Bioservices have?

In the past 10 years, Avid Bioservices' cash and equivalents has ranged from $32.35 million in 2019 to $169.92 million in 2021, and is currently $38.11 million as of their latest financial filing in 2024.

How has Avid Bioservices' book value per share changed over the last 10 years?

Over the last 10 years, Avid Bioservices' book value per share changed from 0.38 in 2014 to 0.96 in 2024, a change of 150.1%.

Related Companies

This page (NASDAQ:CDMO) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avid Bioservices (CDMO) Financials

Frequently Asked Questions About Avid Bioservices' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avid Bioservices (CDMO) Financials

Annual Income Statements for Avid Bioservices

Quarterly Income Statements for Avid Bioservices

Annual Cash Flow Statements for Avid Bioservices

Quarterly Cash Flow Statements for Avid Bioservices

Annual Balance Sheets for Avid Bioservices

Quarterly Balance Sheets for Avid Bioservices

Annual Metrics And Ratios for Avid Bioservices

Quarterly Metrics And Ratios for Avid Bioservices

Frequently Asked Questions About Avid Bioservices' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools